Back to Results
First PageMeta Content
Indoles / Pfizer / Pyrroles / Sunitinib / Renal cell carcinoma / Neuroendocrine tumor / Progression-free survival / Response Evaluation Criteria in Solid Tumors / End point of clinical trials / Medicine / Medical statistics / Organofluorides


NDA[removed]S013 Sutent (sunitinib malate) ODAC Briefing Document FDA Briefing Document
Add to Reading List

Open Document

File Size: 237,95 KB

Share Result on Facebook
UPDATE